{"id":"nct:NCT06549595","kind":"trial","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","authors":["AstraZeneca"],"author_count":1,"year":2024,"published":"2024-08-12","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06549595","source_url":"https://clinicaltrials.gov/study/NCT06549595","archive_url":"https://space-kitty.com/papers/nct:NCT06549595","updated":"2026-10-21","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Untreated Follicular Lymphoma"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1018,"sponsor":"AstraZeneca","conditions":["Untreated Follicular Lymphoma"],"interventions":["DRUG: Surovatamig","DRUG: R-CHOP","DRUG: R-CVP","DRUG: BR"],"start_date":"2024-08-07","start_date_type":"ACTUAL","primary_completion_date":"2031-11-26","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}